Idorsia logo

IDIA - Idorsia Share Price

CHF26.1 0.1  0.5%

Last Trade - 06/08/20

Sector
Healthcare
Size
Large Cap
Market Cap £3.11bn
Enterprise Value £2.99bn
Revenue £57.8m
Position in Universe 214th / 1040
Bullish
Bearish
Unlock IDIA Revenue
Momentum
Relative Strength (%)
1m -18.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -23.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 158.1 60.6 23.8 60.9 34.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Idorsia Ltd revenues increased from SF13.1M to SF58.2M. Net loss applicable to common stockholders decreased 18% to SF189.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 11% to SF190.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IDIA Revenue Unlock IDIA Revenue

Net Income

IDIA Net Income Unlock IDIA Revenue

Normalised EPS

IDIA Normalised EPS Unlock IDIA Revenue

PE Ratio Range

IDIA PE Ratio Range Unlock IDIA Revenue

Dividend Yield Range

IDIA Dividend Yield Range Unlock IDIA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDIA EPS Forecasts Unlock IDIA Revenue
Profile Summary

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated March 3, 2017
Public Since June 16, 2017
No. of Shareholders: n/a
No. of Employees: 636
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange SIX Swiss Exchange
Shares in Issue 142,627,686
Free Float (0.0%)
Eligible for
ISAs
SIPPs
IDIA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IDIA
Upcoming Events for IDIA
Frequently Asked Questions for Idorsia
What is the Idorsia share price?

As of 06/08/20, shares in Idorsia are trading at CHF26.1, giving the company a market capitalisation of £3.11bn. This share price information is delayed by 15 minutes.

How has the Idorsia share price performed this year?

Shares in Idorsia are currently trading at CHF26.1 and the price has moved by 21.76% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Idorsia price has moved by 25% over the past year.

What are the analyst and broker recommendations for Idorsia?

Of the analysts with advisory recommendations for Idorsia, there are there are currently 2 "buy" , 6 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Idorsia is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Idorsia next release its financial results?

Idorsia is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Idorsia dividend yield?

Idorsia does not currently pay a dividend.

Does Idorsia pay a dividend?

Idorsia does not currently pay a dividend.

When does Idorsia next pay dividends?

Idorsia does not currently pay a dividend.

How do I buy Idorsia shares?

To buy shares in Idorsia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Idorsia?

Shares in Idorsia are currently trading at CHF26.1, giving the company a market capitalisation of £3.11bn.

Where are Idorsia shares listed? Where are Idorsia shares listed?

Here are the trading details for Idorsia:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: IDIA
What kind of share is Idorsia?

Based on an overall assessment of its quality, value and momentum, Idorsia is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Idorsia share price forecast 2020?

Shares in Idorsia are currently priced at CHF26.1. At that level they are trading at 33.24% discount to the analyst consensus target price of 0.00.

Analysts covering Idorsia currently have a consensus Earnings Per Share (EPS) forecast of -3.329 for the next financial year.

How can I tell whether the Idorsia share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Idorsia. Over the past six months, the relative strength of its shares against the market has been -1.21%. At the current price of CHF26.1, shares in Idorsia are trading at -6.71% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Idorsia PE Ratio?

We were not able to find PE ratio data for Idorsia.

Who are the key directors of Idorsia?

Idorsia's management team is headed by:

Jean-Pierre Garnier - NEC
Robert Bertolini - NID
Jean-Paul Clozel - CEO
John Greisch - NID
Guy Braunstein - EVP
Martine Clozel - EVP
Andre Muller - CFO
Simon Jose - EVP
Viviane Monges - NID
Mathieu Simon - NID
Who are the major shareholders of Idorsia?

Here are the top five shareholders of Idorsia based on the size of their shareholding:

Clozel (Jean-Paul & Martine) Individual Investor
Percentage owned: 26.2% (37.3m shares)
Johnson & Johnson Corporation
Percentage owned: 7.46% (10.6m shares)
Maag (Rudolf) Individual Investor
Percentage owned: 5.49% (7.82m shares)
Fidelity Management & Research Company Investment Advisor
Percentage owned: 3.51% (5.00m shares)
Artisan Partners Limited Partnership Investment Advisor
Percentage owned: 2.83% (4.02m shares)
Similar to IDIA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.